# Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)

> **NCT00087802** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 383 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** gemcitabine/Eloxatin (GEMOX)
- **DRUG:** carboplatin/paclitaxel (CP)

## Key facts

- **NCT ID:** NCT00087802
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2007-05
- **Final completion:** —
- **Target enrollment:** 383 (ACTUAL)
- **Last updated:** 2009-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087802, "Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00087802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*